2019
A modeling framework to inform preexposure prophylaxis initiation and retention scale-up in the context of 'Getting to Zero' initiatives.
Khanna A, Schneider J, Collier N, Ozik J, Issema R, di Paola A, Skwara A, Ramachandran A, Webb J, Brewer R, Cunningham W, Hilliard C, Ramani S, Fujimoto K, Harawa N. A modeling framework to inform preexposure prophylaxis initiation and retention scale-up in the context of 'Getting to Zero' initiatives. AIDS 2019, 33: 1911-1922. PMID: 31490212, PMCID: PMC6760326, DOI: 10.1097/qad.0000000000002290.Peer-Reviewed Original ResearchConceptsPrEP initiationHIV incidenceYoung Black MSMAgent-based network modelSerodiscordant partnershipsBlack MSMEffective PrEP implementationHigh HIV incidenceHIV-negative individualsNew HIV infectionsPrEP initiatorsPrEP interventionsProphylaxis initiationAntiretroviral therapyPreexposure prophylaxisPrEP implementationPrEP uptakeHIV infectionPrEP useRetention interventionsMean durationCombination interventionsInitiation interventionIncidenceIntervention
2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic features
2014
A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community
Di Paola A, Altice FL, Powell ML, Trestman RL, Springer SA. A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health & Justice 2014, 2: 11. PMID: 25606368, PMCID: PMC4297667, DOI: 10.1186/s40352-014-0011-1.Peer-Reviewed Original ResearchMedical recordsHIV transmission risk behaviorsMini International Neuropsychiatric InterviewCohort of PLWHAPrevalence of PDCombination antiretroviral therapyAntiretroviral treatment adherenceTransmission risk behaviorsInternational Neuropsychiatric InterviewPsychiatric assessment toolsRetrospective data analysisObjective screening toolHIV/AIDSAntiretroviral therapyTreatment adherenceNeuropsychiatric InterviewHigh prevalencePsychiatric diagnosisPLWHARisk behaviorsPD assessmentPD diagnosisUniform screeningScreening toolHealthy outcomesAn evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone